Value proposition

In vitro models to accelerate clinical translation

We’re here to accelerate your therapy’s journey through the complexities of drug discovery and development. Putting innovation at the forefront of our capabilities, industry-leading experts help you confidently and proactively answer critical questions around the safety and efficacy of your product with our gold-standard in vitro models. By harnessing the power of predictive data, we navigate this crucial step efficiently and cost-effectively to maximise the potential of your therapy achieving clinical and market success.

By combining our unique expertise with cutting-edge technologies, we’ve created predictive in vitro models that offer targeted solutions to your complex problems. Our tissue model platforms, including retina, kidney and lung, reliably and accurately mimic in vivo physiology to take the guesswork out of drug development – providing answers to your questions and a window into the future of your therapy.

Our intelligent preclinical models provide the reliable data you need to identify, avoid and mitigate risks and failures. By better understanding how your therapy will interact in vivo, you can make assured decisions to reduce drug attrition and give your safe and efficacious asset the best chance of reaching patients. In a nutshell, we help you save money, save time and save lives by getting ahead of the game.

Induced pluripotent stem cells (iPSCs), Cellular reprogramming and differentiation, Supply of iPSC derived cells for drug development, Sourcing samples for human disease cell lines, Nephrotoxity Testing, ADMET, DIKI, Drug Transport Studies, RPE, Retinal Epithelia, Lung Epithelia, Proximal Tubule Model, Stem Cell Models, Drug Induced Kidney Injury (DIKI), Disease Modelling, Retinal Epithelial Model, Toxicity, Retina, Kidney, and Lung